Common toxicities of mammalian target of rapamycin inhibitors
SA Soefje, A Karnad, AJ Brenner - Targeted oncology, 2011 - Springer
SA Soefje, A Karnad, AJ Brenner
Targeted oncology, 2011•SpringerThe toxicities of newer targeted therapies are different from those seen with the traditional
chemotherapy. Mammalian target of rapamycin (mTOR) inhibitors are evolving into an
important class of drugs in oncology, and this class of drugs presents with a variety of
different toxicities. Although similar to the toxicities seen in transplantation, these rapamycin
analogs have unique side effects when compared to traditional chemotherapy agents. While
most of the toxicities are mild, few can be severe and require routine monitoring. Mucositis …
chemotherapy. Mammalian target of rapamycin (mTOR) inhibitors are evolving into an
important class of drugs in oncology, and this class of drugs presents with a variety of
different toxicities. Although similar to the toxicities seen in transplantation, these rapamycin
analogs have unique side effects when compared to traditional chemotherapy agents. While
most of the toxicities are mild, few can be severe and require routine monitoring. Mucositis …
Abstract
The toxicities of newer targeted therapies are different from those seen with the traditional chemotherapy. Mammalian target of rapamycin (mTOR) inhibitors are evolving into an important class of drugs in oncology, and this class of drugs presents with a variety of different toxicities. Although similar to the toxicities seen in transplantation, these rapamycin analogs have unique side effects when compared to traditional chemotherapy agents. While most of the toxicities are mild, few can be severe and require routine monitoring. Mucositis and rash are the most common side effects. The metabolic toxicities, hyperglycemia, hyperlipidemia, and hypophosphatemia are different from the side effects traditionally seen with chemotherapy. This review will focus on the common toxicities seen with the mTOR inhibitors.
Springer